Alimera Sciences Inc. (NASDAQ:ALIM) shares shot up 25.5% on Thursday . The stock traded as high as $2.10 and last traded at $2.07, with a volume of 5,684,126 shares. The stock had previously closed at $1.65.

Several brokerages have recently weighed in on ALIM. Cowen and Company lowered shares of Alimera Sciences from an “outperform” rating to a “market perform” rating in a report on Thursday, May 5th. Zacks Investment Research upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Monday, June 6th.

The firm’s market capitalization is $92.45 million. The stock has a 50 day moving average price of $1.42 and a 200-day moving average price of $1.82.

Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by $0.03. During the same quarter in the prior year, the firm posted ($0.27) earnings per share. The company earned $5.80 million during the quarter, compared to analysts’ expectations of $5.83 million. The firm’s revenue for the quarter was up 48.7% compared to the same quarter last year. On average, analysts expect that Alimera Sciences Inc. will post ($0.73) earnings per share for the current year.

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.